Intercept Pharmaceuticals, Inc.
ICPTNASDAQHealthcare
$19.00
+$0.04(+0.21%)
Market Cap$794694000
P/E Ratio—
52W High$21.86
52W Low$8.82
Intercept Pharmaceuticals, Inc. (ICPT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ICPT · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2023Report Date: Nov 7, 2023EPS Actual
-$0.07
Est. -$0.27 · +74.1%
Revenue
$0.09B
Est. $0.09B · -2.1%
Fiscal Period
Q4 FY2023
FY ends December
Report Date
Nov 7, 2023
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 2-Quarter EPS Beat Streak
ICPT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2024 | Jul 31, 2024 | — | — | — | — | — | — |
| ◌ Q2 FY2024 | Apr 25, 2024 | — | — | — | — | — | — |
| ◌ Q1 FY2024 | Mar 7, 2024 | -$0.02 | — | — | — | — | — |
| ▲ Q4 FY2023 | Nov 7, 2023 | -$0.27 | -$0.07 | +74.1% | $0.09B | $0.09B | -2.1% |
| ▲ Q3 FY2023 | Aug 2, 2023 | -$0.56 | -$0.14 | +75.0% | $0.08B | $0.08B | +5.2% |
| ▼ Q2 FY2023 | Apr 27, 2023 | -$0.57 | -$0.77 | -35.1% | $0.07B | $0.08B | -15.4% |
| ▲ Q1 FY2023 | Mar 2, 2023 | -$0.53 | -$0.42 | +20.8% | $0.08B | $0.07B | +4.3% |
| ▼ Q4 FY2022 | Nov 1, 2022 | $5.11 | -$3.04 | -159.5% | $0.08B | — | — |
Q3 FY2024
Jul 31, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
Apr 25, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2024
Mar 7, 2024
EPS Actual
—
EPS Est.
-$0.02
EPS Surpr.
—
Revenue
—
Q4 FY2023
Nov 7, 2023Beat
EPS Actual
-$0.07
EPS Est.
-$0.27
EPS Surpr.
+74.1%
Revenue
$0.09B
Q3 FY2023
Aug 2, 2023Beat
EPS Actual
-$0.14
EPS Est.
-$0.56
EPS Surpr.
+75.0%
Revenue
$0.08B
Q2 FY2023
Apr 27, 2023Miss
EPS Actual
-$0.77
EPS Est.
-$0.57
EPS Surpr.
-35.1%
Revenue
$0.07B
Q1 FY2023
Mar 2, 2023Beat
EPS Actual
-$0.42
EPS Est.
-$0.53
EPS Surpr.
+20.8%
Revenue
$0.08B
Q4 FY2022
Nov 1, 2022Miss
EPS Actual
-$3.04
EPS Est.
$5.11
EPS Surpr.
-159.5%
Revenue
$0.08B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2024 | $-1.77 | $-1.48 | $-1.19 | 5 |
| Q4 FY2023 | $-0.36 | $-0.04 | $0.36 | 11 |
| Q3 FY2023 | $-0.75 | $-0.29 | $0.06 | 11 |
| Q2 FY2023 | $-0.94 | $-0.56 | $0.02 | 4 |
| Q1 FY2023 | $-0.95 | $-0.57 | $0.02 | 8 |
| Q4 FY2022 | $-1.79 | $-1.50 | $-1.20 | 19 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2024 | $0.1B | $0.1B | $0.2B | 5 |
| Q4 FY2023 | $0.1B | $0.1B | $0.1B | 11 |
| Q3 FY2023 | $0.1B | $0.1B | $0.1B | 11 |
| Q2 FY2023 | $0.1B | $0.1B | $0.1B | 5 |
| Q1 FY2023 | $0.1B | $0.1B | $0.1B | 9 |
| Q4 FY2022 | $0.1B | $0.1B | $0.1B | 19 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q4 FY2023 | Nov 7, 2023 | +74.1% | $18.96 | $19.00 | +0.21% |
| ▲ Q3 FY2023 | Aug 2, 2023 | +75.0% | $10.50 | $10.91 | +3.90% |
| ▼ Q2 FY2023 | Apr 27, 2023 | -35.1% | $18.34 | $15.97 | -12.92% |
| ▲ Q1 FY2023 | Mar 2, 2023 | +20.8% | $19.81 | $20.58 | +3.89% |
| ▼ Q4 FY2022 | Nov 1, 2022 | -159.5% | $13.87 | $15.73 | +13.41% |
| ▼ Q3 FY2022 | Aug 3, 2022 | -28.3% | $12.25 | $13.84 | +12.98% |
| ▲ Q2 FY2022 | May 6, 2022 | +34.8% | $19.59 | $19.27 | -1.63% |
| ▲ Q1 FY2022 | Mar 2, 2022 | +2.4% | $15.00 | $13.56 | -9.60% |
Q4 FY2023+0.21%
Report Date
Nov 7, 2023
EPS Beat/Miss
+74.1%
Price Before
$18.96
Price After
$19.00
Q3 FY2023+3.90%
Report Date
Aug 2, 2023
EPS Beat/Miss
+75.0%
Price Before
$10.50
Price After
$10.91
Q2 FY2023-12.92%
Report Date
Apr 27, 2023
EPS Beat/Miss
-35.1%
Price Before
$18.34
Price After
$15.97
Q1 FY2023+3.89%
Report Date
Mar 2, 2023
EPS Beat/Miss
+20.8%
Price Before
$19.81
Price After
$20.58
Q4 FY2022+13.41%
Report Date
Nov 1, 2022
EPS Beat/Miss
-159.5%
Price Before
$13.87
Price After
$15.73
Q3 FY2022+12.98%
Report Date
Aug 3, 2022
EPS Beat/Miss
-28.3%
Price Before
$12.25
Price After
$13.84
Q2 FY2022-1.63%
Report Date
May 6, 2022
EPS Beat/Miss
+34.8%
Price Before
$19.59
Price After
$19.27
Q1 FY2022-9.60%
Report Date
Mar 2, 2022
EPS Beat/Miss
+2.4%
Price Before
$15.00
Price After
$13.56
Avg Beat Reaction-0.65%
Avg Miss Reaction+4.49%
Beat Rate5 / 8 quarters
Largest Move+13.41% (Q4 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ICPT ends December
Intercept Pharmaceuticals, Inc. (ICPT) most recently reported earnings on November 7, 2023 for Q4 FY2023, posting EPS of $-0.07 — beating the analyst consensus of $-0.27 by +74.1%. ICPT has beaten EPS estimates for 2 consecutive quarters. The next ICPT earnings date is expected around September 1, 2026.
Each quarter, investors track ICPT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ICPT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ICPT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ICPT earnings · 5 questionsIntercept Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. ICPT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ICPT historically reports after market close (AMC).
ICPT earnings datewhen is ICPT earningsICPT next earnings datewhen does ICPT report earningsICPT earnings calendar
▸ Source: FMP · Intercept Pharmaceuticals, Inc. SEC filings · US GAAP · Intercept Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026